Article
In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
Atherosclerosis - 1 Jul 2014
Postmus Iris, Johnson Paul C D, Trompet Stella, de Craen Anton J M, Slagboom P Eline, Devlin James J, Shiffman Dov, Sacks Frank M, Kearney Patricia M, Stott David J, Buckley Brendan M, Sattar Naveed, Ford Ian, Westendorp Rudi G J, Jukema J Wouter
Abstract excerpt
BACKGROUND: Statin therapy is widely used in the prevention and treatment of cardiovascular events and is associated with significant risk reductions. However, there is considerable variation in response to statin therapy both in terms of LDL cholesterol reduction and clinical outcomes. It has been hypothesized that genetic variation contributes importantly to this individual drug response. METHODS AND RESULTS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.